Osteoprotegerin-Ligand und Osteoprotegerin

Knochengewebe wird kontinuierlich durch einen koordinierten Prozess aus osteoklastärer Resorption und osteoblastärer Bildung erneuert, was zu einem dynamischen Gleichgewicht mit Erhaltung der strukturellen Integrität führt [39]. Einer inadäquat hohen Knochenresorption aufgrund einer gesteigerten Osteoklastenaktivität wird eine zentrale Bedeutung bei der Pathogenese vieler Knochenerkrankungen zugeschrieben, und die Hemmung dieses Prozesses ist ein wichtiges Therapieprinzip [39]. Die Entdeckung und Charakterisierung von Osteoprotegerin-Ligand (OPGL) [2] [27] [47], seines Rezeptors »Receptor activator of nuclear factor-κB« (RANK) [2] und seines Rezeptorantagonisten Osteoprotegerin (OPG) (siehe Glossar, [Tab. 1] [42] haben zu einem neuen, molekularen Konzept der Zellbiologie von Osteoklasten und des Knochenstoffwechsels geführt, in dem diese drei Komponenten eine essentielle Bedeutung einnehmen [18] [44] . In dieser Übersicht stellen wir die Grundlagen und die Regulation von OPGL und OPG durch Zytokine und Hormone dar und diskutieren die klinische Bedeutung dieses Systems für die Pathogenese und Therapie metabolischer Knochenerkrankungen.

Literatur

• 1 Akatsu T, Murakami T, Ono K. et al . Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy.  Bone. 1998;  23 495-498
• 2 Anderson M A, Maraskovsky E, Billingsley W L. et al . A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.  Nature. 1997;  390 175-179
• 3 Bekker P J, Holloway D, Nakanishi A, Arrighi H M, Dunstan C R. Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women.  J Bone Miner Res. 1999;  14 1190 (Suppl 1)
• 4 Bornefalk E, Dahlen I, Johannsson G, Ljunggren O, Ohlsson C. Serum levels of osteoprotegerin: Effects of glucocorticoids and growth hormone.  Bone. 1998;  23 (Suppl 1) F321
• 5 Brown J M, Quinn J E, Buhler K R, Vessella R L. Osteoprotegerin and TRANCE are differentially expressed by prostate cancer cells in vitro and in vivo.  J Bone Miner Res. 1999;  14 1085 (Suppl 1)
• 6 Bucay N, Sarossi I, Dunstan C R. et al . Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.  Genes Dev. 1998;  12 1260-1268
• 7 Burgess T L, Qian Y, Kaufman S. et al . The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.  J Cell Biol. 1999;  145 527-538
• 8 Capparelli C, Kostenuik P J, Morony S. et al . Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.  Cancer Res. 2000;  60 783-787
• 9 Dunstan C R, Capparelli C, Kelley M. et al . Osteoprotegerin (OPG), a novel TNF-receptor family member, profoundly inhibits endosteal bone resorption due to growth, humoral hypercalcemia of malignancy, and interleukin 1.  J Bone Miner Res. 1997;  12 134 (Suppl 1)
• 10 Fuller K, wong B, Fox S, Choi Y, Chambers T J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.  J Exp Med. 1998;  188 997-1001
• 11 Gao Y -H, Shinki T, Yuase T. et al . Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: Regulation of mRNA expression of osteoclast differentiation factor (ODF).  Biochem Biophys Res Commun. 1998;  252 697-702
• 12 Gori F, Hofbauer L C, Dunstan C R. et al . The expression of osteoprogerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.  Endocrinology. 2000;  141 4768-4776
• 13 Hofbauer L C, Dunstan C R, Spelsberg T C, Riggs B L, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphegenetic protein-2, and cytokines.  Biochem Biophys Res Commun. 1998;  250 776-781
• 14 Hofbauer L C, Gori F, Riggs B L. et al . Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis.  Endocrinology. 1999;  140 4382-4389
• 15 Hofbauer L C, Lacey D L, Dunstan C R, Spelsberg T C, Riggs B L, Khosla S. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6 stimulate osteoprotegerin ligand gene expression in human osteoblastic cells.  Bone. 1999;  35 255-259
• 16 Hofbauer L C, Khosla S, Dunstan C R, Lacey D L, Spelsberg T C, Riggs B L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells.  Endocrinology. 1999;  140 4367-4370
• 17 Hofbauer L C, Riggs B L, Dunstan C R, OBrien T, Khosla S. Cyclosporin A and glucocorticoids inhibit osteoprotegerin production in human osteoblastic and coronary smooth muscle cells: Potential mechanism for post-transplant osteoporosis and vascular disease.  J Bone Miner Res. 1999;  14 (Suppl 1) 1174
• 18 Hofbauer L C, Khosla S, Lacey D L, Dunstan C R, Boyle W J, Riggs B L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.  J Bone Miner Res. 2000;  15 2-12
• 19 Horwood N J, Kartsogiannis V, Quinn J MW, Romas E, Martin T J, Gillepsie M T. Activated T cells support osteoclast formation in vitro.  Biochem Biophys Res Commun. 1999;  265 144-150
• 20 Horwood N J, Elliott J, Martin T J, Gillespie M T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells.  Endocrinology. 1998;  139 4743-4746
• 21 Hsu H, Lacey D L, Dunstan C R. et al . Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.  Proc Natl Acad Sci USA. 1999;  96 3540-3545
• 22 Jimi E, Akiyama S, Tsurukai T. et al . Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function.  J Immunol. 1999;  163 434-442
• 23 Kong Y -Y, Yoshida H, Sarosi I. et al . OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.  Nature. 1999;  397 315-323
• 24 Kong Y -Y, Feige U, Sarosi I. et al . Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.  Nature. 1999;  402 304-309
• 25 Kostenuik P J, Morony S, Capparelli C, Lacey D L, Dunstan C R. Comparison of the inhibitory effects of osteoprotegerin and of APD on PTHrP-mediated hypercalcemia and bone remodeling.  J Bone Miner Res. 1999;  14 1135 (Suppl 1)
• 26 Lacey D L, Timms E, Tan H -L. et al . Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation.  Cell. 1998;  93 165-176
• 27 Lee S K, Lorenzo J A. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation.  Endocrinology. 1999;  140 3552-3561
• 28 Li J, Sarosi I, Yan Y -Q. et al . RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism.  Proc Natl Acad Sci USA. 2000;  97 1566-1571
• 29 Lindberg M, Vidal O, Andersson N, Andersson K, Ryberg D, Ohlsson C. Expression and regulation of osteoprotegerin (OPG) and osteoclast differetiation factor (ODF) in mice.  J Bone Miner Res. 1999;  14 F162 (Suppl 1)
• 30 Lomaga M A, Yeh W -C, Sarosi I. et al . TRAF6-deficiency results in osteopetrosis and defective interleukin-1, CD40 and LPS signaling.  Genes Dev. 1999;  13 1015-1024
• 31 Lum L, Wong B R, Josien R. et al . Evidence for a role of a tumor necrosis factor-α (TNF-α)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival.  J Biol Chem. 1999;  274 13 613-13 618
• 32 Manolagas S C, Jilka R L. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis.  N Engl J Med. 1995;  332 305-311
• 33 Menaa C, Barsony J, Reddy S V, Cornish J, Cundy T, Roodman G D. 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Pagets disease.  J Bone Miner Res. 2000;  15 228-236
• 34 Morony S, Capparelli C, Lee R. et al . A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2 D3.  J Bone Miner Res. 1999;  14 1478-1485
• 35 Morony S, Capparelli C, Kostenuik P J. et al . Osteoprotegerin prevents osteolytic bone destruction in both athymic and syngeneic models of experimental tumor metastassis to bone.  J Bone Miner Res. 1999;  14 1125 (Suppl 1)
• 36 Nagai M, Sato N. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation.  Biochem Biophys Res Commun. 1999;  257 719-723
• 37 Neale S D, Itonga I, Smith R, Wass J, Athanasou N A. Humoral factors influencing osteoclast differentiation from circulating mononuclear precursors in Pagets disease.  J Bone Miner res. 1999;  14 SU433 (Suppl 1)
• 38 Roodman G R. Advances in bone biology: The osteoclast.  Endocr Rev. 1996;  17 308-332
• 39 Saika M, Inoue D, Kido S, Matsumoto T. 17β-Estradiol stimulates expression of osteoprotegerin (OPG)/osteoclastogenesis inhibitory factor (OCIF) by a mouse stromal cell line, ST-2.  J Bone Miner Res. 1999;  14 F095 (Suppl 1)
• 40 Shevde N K, Bendixen A C, Maruyama M, Pike J W. Strogen inhibits RANKL stimulated osteoclastogenesis in isolated murine myeloid progenitors and the monocytic/macrophagic cell line RAW 264.7.  J Bone Miner Res. 1999;  14 1070 (Suppl 1)
• 41 Simonet W S, Lacey D L, Dunstan C R. et al . Osteoprotegerin: A novel secreted protein involved in the regulation of bone density.  Cell. 1997;  89 309-319
• 42 Srivastava S K, Weitzmann M N, Chaudhari L R, Namba N, Pacifici R. Estrogen decreases the responsiveness of osteoclast precursors to OPGL by down regulating OPGL induced JNK activity.  J Bone Miner Res. 1999;  14 1178 (Suppl 1)
• 43 Suda T, Takahashi N, Udagawa N, Jimi E, Gillepsie M T, Martin T J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.  Endocr Rev. 1999;  20 345-357
• 44 Thomas R J, Guise T A, Yin J J. et al . Breast cancer cells interact with osteoblasts to support osteoclast formation.  Endocrinology. 1999;  140 4451-4458
• 45 Tomoyasu A, Goto M, Fujise N. et al . Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor.  Biochem Biophys Res Commun. 1999;  245 381-387
• 46 Wong B R, Rho J, Arron J. et al . TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T cells.  J Biol Chem. 1997;  272 25 190-12 194
• 47 Huang L, Xu J, Wood D J, Zheng M H. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-κB in giant cell tumor of bone: Possible involvement in tumor cell-induced osteoclast-like cell formation.  Am J Pathol. 2000;  156 761-767
• 48 Yamamoto M, Murakami T, Nishikawa M. et al . Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyropara-thyroidectomized rat.  Endocrinology. 1998;  139 4012-4015

Korrespondenz